Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KWGRK
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
IMMU-140
|
|||||
| Synonyms |
IMMU140; IMMU 140
Click to Show/Hide
|
|||||
| Organization |
Immunomedics, Inc.; Gilead Sciences, Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 5 Indication(s)
Acute lymphoblastic leukemia [ICD11:2B33]
Clinical candidate
Acute myeloid leukaemia [ICD11:2A60]
Clinical candidate
B-cell lymphoma [ICD11:2A86]
Clinical candidate
Multiple myeloma [ICD11:2A83]
Clinical candidate
Non Hodgkin lymphoma [ICD11:2B33]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
6.1
|
|||||
| Structure |
|
|||||
| Antibody Name |
IMMU-114
|
Antibody Info | ||||
| Antigen Name |
HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA)
|
Antigen Info | ||||
| Payload Name |
Active metabolite of irinotecan SN38
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
CL2A
|
Linker Info | ||||
| Conjugate Type |
Inter-chain cysteine.
|
|||||
| Combination Type |
Govitecan
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.